DNTHDianthus Therapeutics, Inc. /DE/同业对比
Dianthus Therapeutics, Inc. /DE/ 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNTH本股 | $4.6B#12 | — | 3.9x#2 | 2264.8x#7 | -67.3%#7 | -91.1%#13 | -8739.3%#7 | -13.9%#5 | — | — | — | — |
| MRNA | $88.5B#1 | — | 13.1x#8 | 45.5x#3 | -39.9%#6 | 20.8%#5 | -158.1%#3 | -41.7%#11 | -54.6%#3 | — | — | — |
| TWST | $9.6B#4 | — | 21.5x#12 | 25.4x#1 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#7 | -41.4%#2 | — | — | — |
| ORKA | $6.4B#8 | — | 5.8x#4 | — | — | -25.9%#7 | — | -9.5%#4 | — | — | — | — |
| KYMR | $10.8B#3 | — | 6.7x#7 | 275.9x#5 | -16.7%#5 | 39.1%#2 | -891.1%#5 | 19.3%#1 | — | — | — | — |
| VKTX | $3.5B#13 | — | 5.9x#5 | — | — | -227.1%#14 | — | -61.1%#13 | — | — | — | — |
| PRAX | $8.0B#7 | — | 6.0x#6 | — | -100.0%#8 | -65.6%#10 | — | -22.6%#9 | — | — | — | — |
| ERAS | $5.0B#11 | — | 13.9x#9 | — | — | 23.0%#4 | — | -34.4%#10 | — | — | — | — |
| RVMD | $41.0B#2 | — | 15.7x#11 | — | — | -88.5%#12 | — | -43.4%#12 | — | — | — | — |
| RYTM | $6.4B#9 | — | 61.8x#13 | 33.5x#2 | 45.8%#3 | 24.6%#3 | -101.2%#2 | -0.2%#3 | -133.8%#4 | — | — | — |
| CGON | $5.7B#10 | — | 5.6x#3 | 1417.6x#6 | 254.7%#2 | -82.9%#11 | -4722.1%#6 | -15.6%#6 | -18.8%#1 | — | — | — |
| SLS | $2.0B#14 | — | 14.2x#10 | — | -100.0%#8 | 13.0%#6 | — | -19.5%#8 | — | — | — | — |
| PCVX | $9.2B#5 | — | 3.3x#1 | — | — | -65.2%#9 | — | -0.0%#2 | — | — | — | — |
| CYTK | $8.8B#6 | — | — | 99.5x#4 | 376.6%#1 | -33.2%#8 | -695.4%#4 | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议